Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective

Pierre Lévy, David M. Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin and Jean-Baptiste Briere
Additional contact information
Pierre Lévy: LEDa - Laboratoire d'Economie de Dauphine - IRD - Institut de Recherche pour le Développement - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres - CNRS - Centre National de la Recherche Scientifique
David M. Smadja: INSERM - INSERM, l'Institut national de la santé et de la recherche médicale - Ministère de la Santé et de la Recherche
Mondher Toumi: Laboratoire de Santé Publique - Université de la Méditerranée - Aix-Marseille 2, Pharmaco-Epidémiologie - Université Bordeaux Segalen - Bordeaux 2 - INSERM - Institut National de la Santé et de la Recherche Médicale, CEReSS - Centre d'études et de recherche sur les services de santé et la qualité de vie - AMU - Aix Marseille Université

Post-Print from HAL

Keywords: Nonvalvular atrial fibrillation; vitamin K antagonists; international normalised ratio; monitoring; resource use and costs; real-world research; France (search for similar items in EconPapers)
Date: 2019
References: Add references at CitEc
Citations:

Published in Journal of Market Access & Health Policy, 2019, 7 (1), ⟨10.1080/20016689.2018.1564506⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-02271194

DOI: 10.1080/20016689.2018.1564506

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().